TRexBio closed a $50 million extension of its Series B to accelerate clinical testing of its Treg‑activating immunotherapies, including lead candidate TRB‑061 for atopic dermatitis. The financing included investments from Janus Henderson, Alexandria Venture Investments and Eli Lilly among others and follows a prior $84 million Series B in 2024. TRex’s approach targets tumor necrosis factor receptor 2 (TNFR2) to activate regulatory T cells (Tregs) and restore immune balance without broad immunosuppression. The company plans additional early‑stage studies for other pipeline candidates and expects Phase 1 readouts in 2027 for TRB‑061. TRex enters a competitive field of next‑generation eczema and immunomodulatory programs from peers such as Corvus, Apogee, Nektar and large pharma entrants; investors signaled confidence in targeted Treg biology despite crowded clinical space. Management highlighted the proceeds will underwrite dose‑finding and translational work intended to de‑risk clinical milestones and support potential partnering discussions.